FacebookTwitterRedditEmail

FDA Commissioner Hamburg Appointed WHO Deputy?

Many had high hopes for the FDA when Margaret Hamburg was confirmed as Commissioner in 2009 because of her public health background. But she swiftly moved to loosen conflict of interest rules governing those who can serve on FDA expert advisory panels, claiming it was too hard to find experts without Pharma financial links.

Her move followed a Philadelphia Inquirer reporter’s revelations that child psychiatrist Jorge Armenteros, a paid consultant to AstraZeneca, was on an FDA committee voting on–any guesses?–the AstraZeneca drug Seroquel.

Last month, more questions about embedded conflicts of interest at the FDA were raised when Commissioner Hamburg appointed Robert Califf, M.D., chancellor of clinical and translational research at Duke University, as the next FDA Deputy Commissioner for Medical Products and Tobacco despite a thicket of conflicts of interest. It was one of her last official acts before announcing her resignation last week.

A disclosure statement on the website of Duke Clinical Research Institute says “Robert M. Califf, MD, reports receiving research grant support from Novartis Pharmaceuticals, Johnson & Johnson/Scios, Lilly, Merck, and Schering Plough, and consulting fees from Annenberg, Aterovax, Bayer/Ortho McNeil, BMS, Boehringer Ingelheim, GSK, WebMd/theheart.org, Johnson and ohnson/Scios, Kowa Research Institute, McKinsey & Company, Medtronic, Merck, Novartis Pharmaceuticals, Sanofi Aventis, and Schering Plough, and has an equity position with NITROX, LLC.”

In disclosure information for a 2013 article in Circulation, Dr. Califf’s also lists financial links to Gambro, Regeneron, Gilead, AstraZeneca, Roche, others companies and equity positions in four medical companies. The medical website Medscape discloses that Dr. Califf “served as a director, officer, partner, employee, advisor, consultant or trustee for Genentech” as well as for Medscape LLC/theheart.org. Portola Pharmaceuticals says Dr. Califf served on the Board of Directors until he was appointed FDA Deputy Commissioner for Medical Products and Tobacco.

Appearing on PBS with Susan Dentzer after Vioxx was withdrawn because of its links to thousands of heart attacks and stroke, Dr. Califf said, “Merck played by the rules from everything that I’ve seen.” He also said, “many of us consult with the pharmaceutical industry, which I think is a very good thing. They need ideas and then the decision about what they do is really up to the person who is funding the study.” What?

This is not the first time Dr. Califf’s extreme Pharma links have not blocked him from consideration for a top government post. He was up for Dr. Hamburg’s job itself, reported Reutersalong with three others. At the time, some medical voices asked how someone who helps drug companies market their products could possibly be considered as the nation’s chief watchdog over unsafe medications.

Industry conflicts at the FDA cost lives. Recently Senators Joe Manchin (D-W.Va.) and David Vitter (R-La.) questioned whether the FDA’s approval last year of the synthetic opioid Zohydro stemmed from pay-to-play meetings with Big Pharma who allegedly shelled out thousands to meet with regulators. Big Pharma’s hand in the opioid epidemic which causes 17,000 overdose deaths a year in the U.S. is well documented and egregious.

Commissioner Hamburg’s appointment of Dr. Califf amounts to a sad legacy. It also suggests the FDA is no longer even making a pretense at policing industry/government conflicts of interest.

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

bernie-the-sandernistas-cover-344x550
February 26, 2020
Matthew Hoh
Heaven Protect Us From Men Who Live the Illusion of Danger: Pete Buttigieg and the US Military
Jefferson Morley
How the US Intelligence Community is Interfering in the 2020 Elections
Patrick Cockburn
With Wikileaks, Julian Assange Did What All Journalists Should Do
Manuel García, Jr.
Climate Change and Voting 2020
Kollibri terre Sonnenblume
Russiagate: The Toxic Gift That Keeps on Giving
Andrew Bacevich
Going Off-Script in the Age of Trump
Jeremy Kuzmarov
Anti-Russian Xenophobia Reaches Ridiculous Levels
Ted Rall
Don’t Worry, Centrists. Bernie Isn’t Radical.
George Wuerthner
Whatever Happened to the Greater Yellowstone Coalition?
Scott Tucker
Democratic Socialism in the Twenty-First Century
Jonah Raskin
The Call of the Wild (2020): A Cinematic Fairy Tale for the Age of Environmental Disaster
George Ochenski
Why We Shouldn’t Run Government Like a Business
Binoy Kampmark
Julian Assange and the Imperium’s Face: Day One of the Extradition Hearings
Nozomi Hayase
Assange’s Extradition Hearing Reveals Trump’s War on Free Press Is Targeting WikiLeaks Publisher
Peter Harrison
Is It as Impossible to Build Jerusalem as It is to Escape Babylon? (Part Two)
Max Moran
Meet Brad Karp, the Top Lawyer Bankrolling the Democrats
David Swanson
Nonviolent Action for Peace
Ed Sanders
The Ex-Terr GooGoo Eyes “The Russkies Did it!” Plot
February 25, 2020
Michael Hudson
The Democrats’ Quandary: In a Struggle Between Oligarchy and Democracy, Something Must Give
Paul Street
The “Liberal” Media’s Propaganda War on Bernie Sanders
Sheldon Richman
The Non-Intervention Principle
Nicholas Levis
The Real Meaning of Red Scare 3.0
John Feffer
Cleaning Up Trump’s Global Mess
David Swanson
How Are We Going to Pay for Saving Trillions of Dollars?
Ralph Nader
Three Major News Stories That Need To Be Exposed
John Eskow
What Will You Do If the Democrats Steal It from Sanders?
Dean Baker
What If Buttigieg Said That He Doesn’t Accept the “Fashionable” View That Climate Change is a Problem?
Jack Rasmus
The Nevada Caucus and the Desperation of Democrat Elites
Howard Lisnoff
The Powerful Are Going After Jane Fonda Again
Binoy Kampmark
Viral Losses: Australian Universities, Coronavirus and Greed
John W. Whitehead
Gun-Toting Cops Endanger Students and Turn Schools into Prisons
Marshall Sahlins
David Brooks, Public Intellectual
February 24, 2020
Stephen Corry
New Deal for Nature: Paying the Emperor to Fence the Wind
M. K. Bhadrakumar
How India’s Modi is Playing on Trump’s Ego to His Advantage
Jennifer Matsui
Tycoon Battle-Bots Battle Bernie
Robert Fisk
There’s Little Chance for Change in Lebanon, Except for More Suffering
Rob Wallace
Connecting the Coronavirus to Agriculture
Bill Spence
Burning the Future: the Growing Anger of Young Australians
Eleanor Eagan
As the Primary Race Heats Up, Candidates Forget Principled Campaign Finance Stands
Binoy Kampmark
The Priorities of General Motors: Ditching Holden
George Wuerthner
Trojan Horse Timber Sales on the Bitterroot
Rick Meis
Public Lands “Collaboration” is Lousy Management
David Swanson
Bloomberg Has Spent Enough to Give a Nickel to Every Person Whose Life He’s Ever Damaged
Peter Cohen
What Tomorrow May Bring: Politics of the People
Peter Harrison
Is It as Impossible to Build Jerusalem as It is to Escape Babylon?
FacebookTwitterRedditEmail